InnoCan Pharma Balance Sheet Health
Financial Health criteria checks 6/6
InnoCan Pharma has a total shareholder equity of $4.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $9.0M and $4.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$4.60m |
Equity | US$4.71m |
Total liabilities | US$4.33m |
Total assets | US$9.04m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IP4's short term assets ($8.9M) exceed its short term liabilities ($4.3M).
Long Term Liabilities: IP4's short term assets ($8.9M) exceed its long term liabilities ($7.0K).
Debt to Equity History and Analysis
Debt Level: IP4 is debt free.
Reducing Debt: IP4 has no debt compared to 5 years ago when its debt to equity ratio was 13.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IP4 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IP4 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 11.4% each year.